Compound 172 was reported to upregulate the FXR and PPARα expression, as well as downregulated PPARγ expression in HFD-fed rats as a lead molecule for the therapy of NAFLD (Toppo et al., 2018). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.